 price
although rel safe procedur
return key
medic
cah revenu benefit pre-covid stock
up prescript ppe margin
initi look toward outlook like
somewhat less rosi given impact reduc
elect procedur although start come back
greatli reduc level doctor
visit impact rx refil uncertain therefor
despit bet slightli tweak
estim turn see
pandem result econom like suppress
medic pharma volum patient scare
return/coverag loss due unemploy first
half year improv come
calendar therefor despit posit
underli improv mike team
make busi await clearer view
pandem progress rais estim much
also forgotten opioid overhang
time obvious push
unlik disappear
pleas see confer call note
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
like
three key area watch return elect procedur gener sourc avail chang
dont expect elect procedur fulli recov first half see second half
expect net neg impact earn margin
full reduc revenu expect revers pharmaceut sale seen
expect segment
march saw surg pharmaceut sale
experienc averag sale earli quarter
believ acceler due covid pre-purchas
activ radiopharmaci busi slow march due less patient visit
reduc activ impact nuclear busi high margin product higher fix
surg revers
expect declin specialti busi due lower doc visit
anoth consist gener market
expect biggest neg driver even contract renew
expect medic segment
expect similar amount ppe sale despit similar demand
decreas demand higher margin offer like cordi patient recoveri product
abl suppli ppe get replenish
expect volum home lab busi servic busi
segment neg impact substanti declin elect procedur
hurt higher margin product busi though well cost side smaller
revenu busi medic
on-going cost benefit less off-set increment suppli chain cost cost labor forc
premium front-lin worker
lap charg last year off-set declin elect procedur
given relat impact pharma rev increas msd profit could declin msd
year lsd prior guidanc
priorit re-invest busi maintain b/ strength return cash share holder
spend least theyv spent prior year
reduc debt least year
evalu share repo nt prioriti take preced
collect liquid seen signific impact management expect continu
ical busi flu sometim lead season gener tend bit
stronger increas elect procedur
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin may pm et
analyst elizabeth anderson amato primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
